NICE Technology Appraisal 392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Disclaimer: Information intended for healthcare professionals only. The production and printing of this Guidelines Technology Appraisal Card has been funded by AbbVie Ltd. AbbVie Ltd has reviewed this card for technical accuracy and regulatory compliance.
Management of asthma in adults over 65 years of age
Development group: Gruffydd-Jones, McArthur, Murphy, Russell & Wise. This management algorithm was developed by a multidisciplinary expert panel: Gruffydd-Jones K et al with the support of a grant from Teva UK Limited.